Takeda Pharmaceutical Company

Takeda Pharmaceutical Company

Takeda Pharmaceutical Company is a company that provides research-based healthcare and medical products

Takeda Pharmaceutical Company is a company that provides research-based healthcare and medical products. The company was founded by Chobei Takeda I in 1781, in Osaka, Osaka, Japan.

The company is primarily patient-focused, research and development driven, and is interested in biopharmaceuticals. The company operates in the United States with 18,000 employees. The company looks to develop pharmaceutical products and conduct corporate citizenship activities.

COVID-19

Takeda Pharmaceutical Company has announced a plan of action in response to COVID-19. Their plan since the outbreak of the virus is to develop a plasma-derived therapy; an anti-SARS-CoV-2 polyclonal-hyper-immune-globuli that is designed specifically for high risk patients.

The company's therapy includes concentrated pathogen-specific antibodies that are derived from plasma of recovered patients. Takeda Pharmaceuticals Company believes the antibodies have the potential to generate an immune response when injected into a new patient.

Timeline

People

Name
Role
LinkedIn

Bin Li

Director of Computational Biology

Christophe Weber

COO

Yasuchika Hasegawa

CEO

Further reading

Title
Author
Link
Type
Date

What We Do

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Takeda Pharmaceutical Company

Yasuchika Hasegawa

Osaka, Osaka, Japan

Pharmaceuticals and vaccinations

News

Title
Author
Date
Publisher
Description
Transparency Market Research
January 6, 2021
www.prnewswire.com:443
/PRNewswire/ --The demand within the global chronic idiopathic constipation treatment market is rising at a stellar pace in recent times. Advancements in the...
COVID R&D Alliance
November 30, 2020
www.prnewswire.com:443
/PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) -...
BioSpace
November 11, 2020
BioSpace
The collaboration will develop an innovative genomic-based clinical treatment platform The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines
Radiant Insights, Inc.
Invalid Date
www.prnewswire.com:443
SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Global penicillin and streptomycin market are estimated to grow at a substantial CAGR in the forecast period as...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.